In R/R AML patients with TP53 mutations, 47% (n=7/15) demonstrated CR to flotetuzumab and displayed increased tumor inflammation signature as well as CD8, inflammatory chemokine, and PD-1 expression compared with non-responders. Here, PDCD1 is linked to acute myeloid leukemia.